FDA Clearance Tracker · K262599
Biolinq Shine Autonomous Time-in-Range Microsensor
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2026
Substantially Equivalent
Time to decision
53 days
Received Jul 27, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K262599
- Device name
- Biolinq Shine Autonomous Time-in-Range Microsensor
- Applicant
- Biolinq Incorporated
- Applicant location
- San Diego, CA
- Received
- Jul 27, 2026
- Decided
- Sep 18, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Glucose Range Monitoring System (SFU)
- Device class
- Class II
- Regulation
- 21 CFR 862.1359
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SFU. The earliest in FDA's data is DEN240080, decided Sep 23, 2025.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K262599
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Biolinq Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Biolinq Shine Autonomous Time-in-Range MicrosensorNew device typeDe Novo
DEN240080 · Decided Sep 23, 2025 · 270 days after receipt
Device type: Glucose Range Monitoring System (SFU) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.